{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:52:39Z","timestamp":1773841959724,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cardfail.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:27:24Z","timestamp":1747459644000},"page":"633-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors: Agent Comparison With Implications for Clinical Practice and Trial Design"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"JO\u00c3O PEDRO","family":"FERREIRA","sequence":"first","affiliation":[]},{"given":"PEDRO","family":"MARQUES","sequence":"additional","affiliation":[]},{"given":"ANA RITA","family":"LEITE","sequence":"additional","affiliation":[]},{"given":"JO\u00c3O S\u00c9RGIO","family":"NEVES","sequence":"additional","affiliation":[]},{"given":"FAIEZ","family":"ZANNAD","sequence":"additional","affiliation":[]},{"given":"BERTRAM","family":"PITT","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.05.002_bib0001","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0003","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0004","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0006","first-page":"ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-85-5-630","article-title":"Spironolactone and endocrine dysfunction","volume":"85","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0009","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0010","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone: results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0012","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4158\/EP-2020-0277","article-title":"Mineralocorticoid receptor antagonists decrease the rates of positive screening for primary aldosteronism","volume":"26","author":"Tezuka","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2265.1978.tb01510.x","article-title":"Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men","volume":"9","author":"Miyatake","year":"1978","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvac027","article-title":"Aldosterone and cardiovascular diseases","volume":"119","author":"Parksook","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00004872-200018030-00001","article-title":"The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"18","author":"Ferrari","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.06054","article-title":"Rac1-mediated activation of mineralocorticoid receptor in pressure overload-induced cardiac injury","volume":"67","author":"Ayuzawa","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0017","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41440-024-01970-7","article-title":"Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism","volume":"48","author":"Yoshida","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0020","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low-dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0022","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","article-title":"Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0026","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0027","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0028","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0029","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0030","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0031","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0032","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.002_bib0033","first-page":"236","article-title":"Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials","volume":"56","author":"Ferreira","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0034","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0036","doi-asserted-by":"crossref","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.002_bib0037","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT: new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT: new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0041","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0042","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.002_bib0044","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Causland","year":"2024","journal-title":"JACC"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0046","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0047","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0049","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0051","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cardfail.2025.05.002_bib0052","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00392-022-02116-w","article-title":"Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial","volume":"112","author":"Ferreira","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0054","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM198707163170304","article-title":"Equipoise and the ethics of clinical research","volume":"317","author":"Freedman","year":"1987","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.cardfail.2025.05.002_bib0055","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0056","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0057","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0058","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0059","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of Spironolactone in Patients with Resistant Arterial Hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0060","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0061","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0062","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0063","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0064","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","article-title":"Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study","volume":"47","author":"Kario","year":"2024","journal-title":"Hyperten Res"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0065","first-page":"2219","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0066","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0067","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0068","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0069","doi-asserted-by":"crossref","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"M\u00e5rup","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0070","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0071","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cardfail.2025.05.002_bib0072","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0073","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0074","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.05.002_bib0076","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425002039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:31:36Z","timestamp":1773135096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425002039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1071916425002039"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.002","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors: Agent Comparison With Implications for Clinical Practice and Trial Design","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}